SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 2.55% Passive Stake in Windtree Therapeutics

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a passive beneficial ownership of 2.55% in Windtree Therapeutics, Inc. as of December 31, 2024.

Summary

• Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Windtree Therapeutics, Inc.
• As of December 31, 2024, the Reporting Persons beneficially own an aggregate of 288,552 shares of Windtree Therapeutics, Inc. Common Stock.
• This ownership represents 2.55% of the total class of securities outstanding.
• The percentage is based on 11,337,380 shares outstanding as of December 20, 2024, as reported by Windtree Therapeutics, Inc. in its Schedule 14A.
• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, as the managing member of Armistice Capital, LLC, is deemed to beneficially own the shares held by the Master Fund.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate a positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant passive ownership stake by an investment firm and its principal.

Key Dates

Keywords

Windtree Therapeutics, Armistice Capital, Steven Boyd, Schedule 13G, beneficial ownership, common stock, SEC filing, investment management, passive investment